IL6R and cancer: Previous studies have demonstrated that chemotherapy activates NF-κB via the AKT-IκB pathway [15–18] and STAT3 via the IL-6R/JAK1 pathway, leading to PD-L1 expression and contributing to chemotherapy resistance in cancer cells [25].